Endo International PLC (ENDP) Stock Rating Reaffirmed by Mizuho
Endo International PLC (NASDAQ:ENDP) (TSE:ENL)‘s stock had its “buy” rating reaffirmed by research analysts at Mizuho in a report issued on Tuesday. They presently have a $14.00 price target on the stock, down from their previous price target of $19.00. Mizuho’s price target suggests a potential upside of 50.86% from the stock’s previous close.
A number of other research analysts also recently commented on ENDP. Oppenheimer Holdings, Inc. reaffirmed a “hold” rating on shares of Endo International PLC in a research note on Sunday, July 23rd. Deutsche Bank AG dropped their price target on Endo International PLC from $18.00 to $15.00 and set a “buy” rating for the company in a research note on Friday, July 7th. Vetr raised Endo International PLC from a “strong sell” rating to a “sell” rating and set a $11.34 price target for the company in a research note on Wednesday, May 17th. ValuEngine downgraded Endo International PLC from a “buy” rating to a “hold” rating in a research note on Friday, September 1st. Finally, Zacks Investment Research downgraded Endo International PLC from a “hold” rating to a “sell” rating in a research note on Tuesday, July 11th. Three research analysts have rated the stock with a sell rating, sixteen have assigned a hold rating and five have issued a buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus target price of $14.49.
Endo International PLC (ENDP) traded up 2.425% during midday trading on Tuesday, hitting $9.505. 3,201,162 shares of the stock traded hands. The stock’s market capitalization is $2.12 billion. Endo International PLC has a 12-month low of $7.41 and a 12-month high of $23.98. The firm’s 50 day moving average is $9.16 and its 200-day moving average is $10.99.
Endo International PLC (NASDAQ:ENDP) (TSE:ENL) last posted its earnings results on Tuesday, August 8th. The company reported $0.93 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.74 by $0.19. Endo International PLC had a positive return on equity of 37.58% and a negative net margin of 126.93%. The company had revenue of $875.73 million during the quarter, compared to the consensus estimate of $832.66 million. During the same quarter last year, the firm earned $0.86 earnings per share. The company’s revenue was down 4.9% on a year-over-year basis. On average, analysts anticipate that Endo International PLC will post $3.51 EPS for the current fiscal year.
ILLEGAL ACTIVITY WARNING: This article was first published by Daily Political and is owned by of Daily Political. If you are reading this article on another website, it was illegally stolen and reposted in violation of international trademark & copyright laws. The legal version of this article can be accessed at https://www.dailypolitical.com/2017/09/12/endo-international-plc-endp-stock-rating-reaffirmed-by-mizuho.html.
In other news, CEO Paul Campanelli purchased 6,500 shares of Endo International PLC stock in a transaction dated Monday, August 14th. The shares were bought at an average cost of $7.71 per share, for a total transaction of $50,115.00. Following the completion of the acquisition, the chief executive officer now owns 213,620 shares in the company, valued at approximately $1,647,010.20. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website. Also, COO Terrance J. Coughlin purchased 20,000 shares of Endo International PLC stock in a transaction dated Thursday, August 10th. The shares were purchased at an average price of $7.70 per share, for a total transaction of $154,000.00. Following the completion of the acquisition, the chief operating officer now owns 181,369 shares of the company’s stock, valued at approximately $1,396,541.30. The disclosure for this purchase can be found here. Over the last 90 days, insiders have bought 36,000 shares of company stock worth $279,460. Company insiders own 0.50% of the company’s stock.
Several large investors have recently added to or reduced their stakes in the company. James Investment Research Inc. bought a new stake in Endo International PLC in the second quarter valued at approximately $113,000. Blair William & Co. IL bought a new stake in Endo International PLC in the second quarter valued at approximately $126,000. Point View Wealth Management Inc. boosted its holdings in Endo International PLC by 16.6% in the second quarter. Point View Wealth Management Inc. now owns 13,331 shares of the company’s stock valued at $149,000 after acquiring an additional 1,900 shares during the last quarter. Riverhead Capital Management LLC boosted its holdings in Endo International PLC by 64.4% in the second quarter. Riverhead Capital Management LLC now owns 15,025 shares of the company’s stock valued at $168,000 after acquiring an additional 5,887 shares during the last quarter. Finally, Bank of Hawaii bought a new stake in Endo International PLC in the second quarter valued at approximately $180,000. Institutional investors own 90.74% of the company’s stock.
About Endo International PLC
Endo International PLC, formerly Endo Health Solutions Inc is a specialty healthcare solutions company focused on branded and generic pharmaceuticals, devices and services. The Company has a portfolio of branded pharmaceuticals that includes brands, such as Lidoderm, Opana ER, Voltaren Gel, Percocet, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel.
Receive News & Ratings for Endo International PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International PLC and related companies with MarketBeat.com's FREE daily email newsletter.